Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omidenepag isopropyl - Santen Pharmaceutical/Ube Industries

Next Previous
Drug Profile

Omidenepag isopropyl - Santen Pharmaceutical/Ube Industries

Alternative Names: DE-117; DE-117B; EYBELIS; OMLONTI; STN-1011700; STN10117

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ube Industries
  • Developer Santen Pharmaceutical; Ube Industries
  • Class Antiglaucomas; Pyrazoles; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Open-angle glaucoma

Most Recent Events

  • 28 Nov 2024 Phase-III clinical trials in Ocular hypertension in China (Ophthalmic) (NCT06666855)
  • 28 Nov 2024 Phase-III clinical trials in Open-angle glaucoma in China (Ophthalmic) (NCT06666855)
  • 04 Nov 2024 Santen Pharmaceuticals plans a phase III trial for Glaucoma or Ocular hypertension (Ophthalmic), in November 2024 (NCT06666855)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top